Rx-TO-OTC SWITCHES: ROLE OF FOREIGN DATA IN NDA REVIEWS
This article was originally published in The Tan Sheet
Executive Summary
Rx-TO-OTC SWITCHES: ROLE OF FOREIGN DATA IN NDA REVIEWS is one of several issues the OTC drug industry is looking to FDA to clarify, Nonprescription Drug Manufacturers Association Senior VP- Science & Technology William Soller, PhD, said at NDMA's annual marketing seminar in New York City on Jan. 12. Soller suggested that it "would be helpful in today's [regulatory] environment in relation to switch decisions" to have a "clearer understanding" of how foreign data will "be utilized by FDA to evaluate switch safety and effectiveness."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning